Diabetes Obesity & Metabolism

Article	Citations
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry	635
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment	248
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh	153
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Resul	147
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover	144
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis	129
Incidence of chronic kidney disease among adults with prediabetes in the CURE ‐ CKD registry, 2013	108
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	96
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia	96
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	86
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis	86
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar	85
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups	79
	77
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease	76
Issue Information	74
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes	74
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐bli	72
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy	63
The effects of antihypertensive drugs on glucose metabolism	62
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis	62
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study	62
The benefit of dexamethasone in patients with COVID ‐19 infection is preserved in patients with diabetes	55
Front Cover	55
Long‐term effects of metformin on offspring health: A review of current evidence and future directions	54

Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis	53
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity	53
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes	53
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’	53
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study	50
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial	50
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”	50
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors	49
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes	48
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin	47
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c	46
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study	46
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada	45
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status	45
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pum	45
Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized	44
Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis	43
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic	43
Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study	42
Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–2019	42
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial	41
CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination	41
Diabetes, Obesity and Metabolism	41
Adaptive bolus calculators for people with type 1 diabetes: A systematic review	40
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?	40
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial	39
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial	38
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic	38
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes	38
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy	38
Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study	38
Effects of CB1R inverse agonist, INV ‐202, in patients with features of metabolic syndrome. A rand	37
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020	37
Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes	37
Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2	36
Issue Information	35
Comparative efficacy of sleeve gastrectomy with fundoplication versus standard sleeve gastrectomy in obesity and gastroesophageal reflux disease: A randomised trial	35
Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence	35
Risk of depression with GLP ‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study	35
Similarities and differences in the intestinal actions of metformin and imeglimin	34
Interrupting prolonged sitting reduces postprandial GIP but not GLP‐1 responses in type 2 diabetes	34
Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomise	34
Correction to “Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of a	34
Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study	33
Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized	33
Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data	33
Diabetes and incident stroke and mediation by microvascular dysfunction: Pooled analysis of three population‐based studies	33
Associations of metabolic syndrome with cognitive function and dementia risk: Evidence from the UK Biobank cohort	33
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study	33
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US ‐lice	33

Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network	32
Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age	32
Cross‐sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes	31
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial	31
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme	31
Safety and efficacy of an oral insulin ( Capsulin ) in patients with early‐stage type 2 diabetes: A dose‐ranging phase 2b	31
Impaired awareness of hypoglycaemia: Prevalence and associated factors before and after FreeStyle L ibre use in the Associat	31
Molecular signatures of brain glycolysis dysfunction in Alzheimer's disease	30
Effects of reducing sedentary behaviour on renal glucose uptake during insulin stimulation: A post‐hoc analysis of a 6‐month randomized controlled trial	30
Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based co	30
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on	30
Development and validation of a novel method for evaluation of multiple islet autoantibodies in dried blood spot using dissociation‐enhanced lanthanide fluorescent immunoassays technology, specific an	29
Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA	29
Nomogram model and risk score to predict 5‐year risk of progression from prediabetes to diabetes in Chinese adults: Development and validation of a novel model	29
The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021	28
Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases	28
The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials	28
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of	28
Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double‐blind, placebo‐controlled trial	28
Generating real‐world evidence on diabetes technology using the CareLink Personal data management system	28
Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico	28
Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study	28
Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan	27
Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐	27
Exploring new frontiers: Effects of psychedelics on neurotransmitter‐regulated glucagon release in pancreatic islets	27
A low n‐6 to n‐3 polyunsaturated fatty acid ratio diet improves hyperinsulinaemia by restoring insulin clearance in obese youth	27
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial	27
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysi	27
SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial	27
Five‐year trajectories of HbA1c by age, sex, ethnicity and deprivation in adults with newly diagnosed type 2 diabetes: Observational study in England	27
Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study	27
	27
Diabetes, Obesity and Metabolism	27
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre	27
Beta cell function and global glucose metabolism are impaired in Dp(16)1Yey mouse model of Down syndrome	27
Targeting the cholinergic anti‐inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study	26
Accelerated onset of diabetes in non‐obese diabetic mice fed a refined high‐fat diet	26
The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus	26
Outcomes of hybrid closed‐loop insulin delivery activated 24/7 versus evening and night in free‐living prepubertal children with type 1 diabetes: A m	26
Validation of the Individualized Metabolic Surgery score in predicting long‐term remission of diabetes after duodenal switch‐type procedures	26
Front Cover	26
Postnatal glycaemic outcomes in women with high‐risk gestational diabetes: Identifying key predictors for early intervention	26
Cardiorenal benefits of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in type 2 diabetes without cardiovascular and renal diseases	26
Healthy lifestyle and all‐cause and cause‐specific dementia in individuals with type 2 diabetes and the roles of diabetes duration and insulin use in UK	26
Glycated haemoglobin, HOMA2‐B , C‐peptide to glucose ratio and type 2 diabetes clusters as predict	25
Positive allosteric γ‐aminobutyric acid type A receptor modulation prevents lipotoxicity‐induced injury in hepatocytes in vitro	25
Future diabetes risk can be predicted by the number of abnormal oral glucose tolerance test values during pregnancy	25
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes	25
Association of single‐point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes	25
Current insulin infusion set failure criteria may be too stringent for real‐life settings and may skew infusion set failure outcomes in extended‐wear infusion set studies	24
Issue Information	24
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI	24
Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure	24
Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium‐glucose cotransporter 2 inhibitors? A correlation meta‐analysis	24
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in h	24
Effect of saroglitazar on glycaemic parameters: A systematic review and meta‐analysis of randomized controlled trials	24
Effect of renin‐angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look	24
Comments on ‘Propensity score matching methodology in Riley et al.'s study on type 2 diabetes and obstructive sleep apnoea’	24
Neural pathways to bariatric success: What explainable AI reveals that conventional fMRI methods may miss	23
The effect of sugarcane extract supplementation on glycemic control in a mouse model of type 1 diabetes	23
Front Cover	23
Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes	23
Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study	23
Metabolically healthy obesity and cardiovascular events: A risk of obesity	23
Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP	23
Baseline clinical factors associated with diabetes distress in dialysis patients: Insights from the ABCD audit data	23
Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐re	23
Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID ‐19:	23
Male–female differences in insulin sensitivity and β‐cell function in US elders with and without abdominal obesity: An exploratory study with an in‐d	22
Incidence and risk factors of new‐onset diabetes mellitus: A five‐year follow‐up study in solid organ transplant recipients in Germany	22
Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies	22
Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time‐in‐ranges in Chinese adults	22
Sick days glycaemic outcomes in a cohort of children and adolescents with type 1 diabetes using an AID system—A preliminary report	22
Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with	22
Changes in remnant cholesterol and the incidence of diabetes: Results from two large prospective cohort studies	22
	22
Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes	22
Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real‐world prospective cohort study	21
Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabete	21
Association of body roundness index with cardiovascular disease and all‐cause mortality among Chinese adults	21

The impact of family history of type 2 diabetes on clinical heterogeneity in idiopathic type 1 diabetes	21
Acidosis is associated with lower insulin sensitivity and incident type 2 diabetes in indigenous Americans: A prospective cohort study	21
Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials	21
Glycaemia and cardiac arrhythmias in people with type 1 diabetes: A prospective observational study	21
Diabetes, Obesity and Metabolism	21
Challenging the 50‐50 rule for the basal‐bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control	21
Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis	21
Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials	21
Novel metabolic and inflammatory stratification of overweight/obesity to characterize risks of adverse outcomes: A large population‐based cohort study	21
Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome	21
Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight	21
Diabetes, Obesity and Metabolism	21
Altered high‐density lipoprotein composition is associated with risk for complications in type 2 diabetes mellitus in South Asian descendants: A cross‐sectional, case‐control study on lipoprotein subc	20
Polarized macrophages promote gestational beta cell growth through extracellular signal‐regulated kinase 5 signalling	20
Front Cover	20
Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched coho	20
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule gl	20
Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japa	20
Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks	20
Growth differentiation factor 15 ( GDF15 ) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms	20
Low levels of soluble neuropilin‐1 were associated with depression in adults with newly diagnosed type 2 diabetes	20
	20
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis	20
Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis	20
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE rando	20
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis	20
Dapagliflozin modulates hepatic lipid metabolism through the proprotein convertase subtilisin/kexin type 9/low density lipoprotein receptor pathway	20
Bone marrow metabolism is affected by body weight and response to exercise training varies according to anatomical location	20
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes	20
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized do	20
The interaction effect between BMI , diabetes and age at diabetes onset on the risk of thyroid cancer: A population‐based cohort study in Shanghai, C	19
Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease:	19
Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial	19
Frequency and sequence of proteinuria positivity and clinical outcomes in patients with diabetes: A nationwide cohort study	19
Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 st	19
Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?	19
Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DP	19
Glucose‐dependent insulinotropic polypeptide counteracts diet‐induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin‐responsive and proopiomelanocortin neurons in	19
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase	19
S odium‐glucose co‐transporter‐2 inhibitors: Writing the next chapter of a unique success story	19
Impact of time in tight range on all‐cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study	19
Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity	19
Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China‐PAR	18
Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐	18
Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study	18
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated w	18
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease	18
Barriers to early diagnosis of chronic kidney disease and use of sodium‐glucose cotransporter‐2 inhibitors for renal protection: A comprehensive review and call to action	18
Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida +	18
Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes	18
Impact of a very low‐calorie ketogenic diet on metabolic and microbiota outcomes in post‐bariatric patients and bariatric‐Naïve individuals: A comparative pilot study	18
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system	18
When can weekly anti‐obesity peptides be used for monthly administration?	18
Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta‐analysis of randomized controlled trials	18
Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase	18
Front Cover	18
The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management	18
Cover Image, Volume 24, Issue 12	18
Global cardiometabolic alliance: A clinical and research initiative addressing the 21st century pandemic of insulin resistance‐associated disease	18
Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials	18
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism	18
Glycaemic treatment of newly diagnosed type 2 diabetes	18
Effect of glucagon‐like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta‐analysis	17
Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials	17
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review	17
Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND	17
GABA ameliorates diet‐induced hepatic steatosis and insulin resistance by inhibiting macrophage activation	17
Exercise‐related hypoglycaemia induces QTc ‐interval prolongation in individuals with type 1 diabetes	17
Genetic evidence for the effects of glucokinase activation on frailty‐related outcomes: A Mendelian randomisation study	17
Sex‐specific associations between skeletal muscle mass and incident diabetes: A population‐based cohort study	17
Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes	17
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year S	17
Risk factor control and incident cardiovascular disease in patients with diabetes: Sex‐specific relations	17
An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implic	17
Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes	17
Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study	17
Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population	17
Genomic risk prediction for type 2 diabetes in Australian individuals aged 70 years and older	17
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the	17
Somatic and mental symptoms associated with dysglycaemia, diabetes‐related complications and mental conditions in people with diabetes: Assessments in daily life using continuous glucose monitoring an	16
Fat‐to‐muscle ratio is associated with insulin resistance and cardiometabolic disorders in adults with type 1 diabetes mellitus	16
Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts	16
Trends in anti‐diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009–2013	16
Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada	16
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes	16
Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis	16
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis	16
Initial antibiotic therapy for postoperative moderate or severe diabetic foot infections: Broad versus narrow spectrum, empirical versus targeted	16
Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR‐T1D study	16
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and	16
Neighbourhood‐level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes	16
	16
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses	16
The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity	16
Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes	16